Literature DB >> 6798600

Binding of antiparkinsonian ergot derivatives to the dopamine receptor.

R L Weir, R E Hruska, E K Silbergeld.   

Abstract

The effects of bromocriptine, lisuride and apomorphine on specific binding of 3H-spiroperidol to homogenates of rat caudate nucleus were studied. (+)-Butaclamol was used to define specific binding. Bromocriptine and lisuride inhibited binding markedly, in vitro and also 30 min after in vivo injection. Bromocriptine continued to inhibit binding 24h after a single injection and also after 4 days of drug administration. Lisuride did not affect net specific binding at these periods. Apomorphine produced a mild reduction in binding after 30 min but none after 4 days. It appears that the ergot alkaloids inhibit binding of 3H-spiroperidol by binding strongly to the dopamine receptor.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6798600     DOI: 10.1007/BF00432172

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  20 in total

1.  Lisuride in Parkinson's disease.

Authors:  M Schachter; J Blackstock; J P Dick; R J George; C D Marsden; J D Parkes
Journal:  Lancet       Date:  1979-11-24       Impact factor: 79.321

Review 2.  Treatment of Parkinson's disease with dopamine agonists: a review.

Authors:  A Lieberman; A Neophytides; M Kupersmith; I Casson; R Durso; S H Foo; M Khayali; T Tartaro; M Goldstein
Journal:  Am J Med Sci       Date:  1979 Jul-Aug       Impact factor: 2.378

3.  Clinical effectiveness of lisuride hydrogen maleate: a double-blind trial versus methysergide.

Authors:  W M Herrmann; R Horowski; K Dannehl; U Kramer; K Lurati
Journal:  Headache       Date:  1977-05       Impact factor: 5.887

4.  Differential effects of three dopamine agonists: apomorphine, bromocriptine and lergotrile.

Authors:  E K Silbergeld; R F Pfeiffer
Journal:  J Neurochem       Date:  1977-06       Impact factor: 5.372

5.  Dopamine agonists reverse the elevated 3H-neuroleptic binding in neuroleptic-pretreated rats.

Authors:  S J List; P Seeman
Journal:  Life Sci       Date:  1979-04-16       Impact factor: 5.037

6.  Treatment of Schizophrenia with ergot derivatives.

Authors:  C A Tamminga; M H Schaffer
Journal:  Psychopharmacology (Berl)       Date:  1979       Impact factor: 4.530

7.  Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan.

Authors:  D G Grahame-Smith
Journal:  J Neurochem       Date:  1971-06       Impact factor: 5.372

8.  Bromocriptine treatment of secondary amenorrhoea.

Authors:  M Seppalå; E Hirvonen; T Ranta
Journal:  Lancet       Date:  1976-05-29       Impact factor: 79.321

9.  Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man.

Authors:  W H Aellig; E Nüesch
Journal:  Int J Clin Pharmacol Biopharm       Date:  1977-03

10.  Evidence for an irreversible interaction of bromocryptine with central dopamine receptors.

Authors:  M J Bannon; A A Grace; B S Bunney; R H Roth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-05       Impact factor: 3.000

View more
  3 in total

Review 1.  The motor effects of bromocriptine--a review.

Authors:  D M Jackson; O F Jenkins; S B Ross
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 2.  Hypothesis: bromocriptine lacks intrinsic dopamine receptor stimulating properties.

Authors:  D M Jackson; O F Jenkins
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

3.  Locomotor effects of lisuride: a consequence of dopaminergic and serotonergic actions.

Authors:  H Fink; R Morgenstern
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.